Company
QurAlis
We believe a cure or treatment should exist for every disease and every person.
Also known as QurAlis Corporation
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Cambridge, MA, United States
- Founded
- 2016
- Legal name
- QurAlis Corporation
- quralis.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
At QurAlis, we consider ourselves “neuro pioneers” because we are driven to explore the deepest aspects of human neurology in order to find the treatments patients urgently need. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that have the potential to alter the trajectory of ALS, FTD, and other neurodegenerative and neurological diseases.
Funding snapshot
- Total raised
- $118MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series B, $88M2023-03-09
Funding rounds
- Round, 2025
- $20M2025-08-21, SEC form D sold, 19 investors
- Series B
- $88M2023-03-09, Company stated
- Round, 2022
- $60M2022-12-20, SEC form D sold, 27 investors
- Round, 2022
- $5M2022-08-12, SEC form D sold, 19 investors
- Round, 2020
- $33.2M2020-05-01, SEC form D sold, 25 investors
Products
- Web
- FlexASO®
- Other
- QRL-101
- Web
- QRL-101
- Other
- QRL-201
- Web
- QRL-201
- Web
- QRL-204
Loading relationship preview